

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
04 April 2024 (04.04.2024)



(10) International Publication Number
WO 2024/073618 A3

(51) International Patent Classification:
C12N 15/113 (2010.01) A61K 31/713 (2006.01)

(21) International Application Number:
PCT/US2023/075446

(22) International Filing Date:
28 September 2023 (28.09.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/377,715 29 September 2022 (29.09.2022) US

(71) Applicant: ATALANTA THERAPEUTICS, INC.
[US/US]; 51 Sleeper Street, 7th Floor, Boston, MA 02210 (US).

(72) Inventors: GALLANT-BEHM, Corrie; 44 Mansfield Rd, Wellesley, MA 02481 (US). HASSLER, Matthew; 126 Border St, Apt 512, Boston, MA 02128 (US). CURTIS,

Daniel; 57 Brettwood Rd, Belmont, MA 02478 (US). DA CRUZ GODINHO, Bruno, Miguel; 4 Fielding Rd, Reading, MA 01867 (US).

(74) Agent: QUARTARARO, Justin, S. et al.; Clark & Elbing LLP, 101 Federal Street, 15th Floor, Boston, MA 02110 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: SIRNA COMPOSITIONS AND METHODS TARGETING MICROTUBULE ASSOCIATED PROTEIN TAU NUCLEIC ACIDS




FIG. 1A

(57) Abstract: The instant application is directed to single- or double-stranded interfering RNA molecules (e.g., siRNA) that target a microtubule-associated protein tau (MAPT) gene. The interfering RNA molecules may contain specific patterns of nucleoside modifications and internucleoside linkage modifications, as pharmaceutical compositions including the same. The siRNA molecules may be branched siRNA molecules, such as di-branched, tri-branched, or tetra-branched siRNA molecules. The disclosed siRNA molecules may further feature a 5' phosphorus stabilizing moiety and/or a hydrophobic moiety. Additionally, the disclosure provides methods for delivering the siRNA molecule of the disclosure to the central nervous system of a subject, such as a subject identified as having a tauopathy.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:

18 July 2024 (18.07.2024)